Proteomic classification of breast cancer

Dalia Kamel, Bernadette Brady, Adel Tabchy, Gordon Mills, Bryan Hennessy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

Original languageEnglish (US)
Pages (from-to)1495-1509
Number of pages15
JournalCurrent Drug Targets
Volume13
Issue number12
DOIs
StatePublished - Dec 3 2012
Externally publishedYes

Fingerprint

Proteomics
Breast Neoplasms
Assays
Immunosorbents
Proteins
Medical problems
Technology
Protein Array Analysis
Mass spectrometry
Immunoblotting
Availability
Mass Spectrometry
Age Groups
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Enzymes
Health

Keywords

  • Breast cancer
  • Molecular technology
  • Proteome
  • RPPA

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Kamel, D., Brady, B., Tabchy, A., Mills, G., & Hennessy, B. (2012). Proteomic classification of breast cancer. Current Drug Targets, 13(12), 1495-1509. https://doi.org/10.2174/138945012803530080

Proteomic classification of breast cancer. / Kamel, Dalia; Brady, Bernadette; Tabchy, Adel; Mills, Gordon; Hennessy, Bryan.

In: Current Drug Targets, Vol. 13, No. 12, 03.12.2012, p. 1495-1509.

Research output: Contribution to journalArticle

Kamel, D, Brady, B, Tabchy, A, Mills, G & Hennessy, B 2012, 'Proteomic classification of breast cancer', Current Drug Targets, vol. 13, no. 12, pp. 1495-1509. https://doi.org/10.2174/138945012803530080
Kamel, Dalia ; Brady, Bernadette ; Tabchy, Adel ; Mills, Gordon ; Hennessy, Bryan. / Proteomic classification of breast cancer. In: Current Drug Targets. 2012 ; Vol. 13, No. 12. pp. 1495-1509.
@article{333820572e954b529d3cd460099314da,
title = "Proteomic classification of breast cancer",
abstract = "Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.",
keywords = "Breast cancer, Molecular technology, Proteome, RPPA",
author = "Dalia Kamel and Bernadette Brady and Adel Tabchy and Gordon Mills and Bryan Hennessy",
year = "2012",
month = "12",
day = "3",
doi = "10.2174/138945012803530080",
language = "English (US)",
volume = "13",
pages = "1495--1509",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Proteomic classification of breast cancer

AU - Kamel, Dalia

AU - Brady, Bernadette

AU - Tabchy, Adel

AU - Mills, Gordon

AU - Hennessy, Bryan

PY - 2012/12/3

Y1 - 2012/12/3

N2 - Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

AB - Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

KW - Breast cancer

KW - Molecular technology

KW - Proteome

KW - RPPA

UR - http://www.scopus.com/inward/record.url?scp=84870183727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870183727&partnerID=8YFLogxK

U2 - 10.2174/138945012803530080

DO - 10.2174/138945012803530080

M3 - Article

C2 - 22974393

AN - SCOPUS:84870183727

VL - 13

SP - 1495

EP - 1509

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -